CompletedNCT07371325
Official study titleEfficacy of Pediococcus Acidilactici as add-on to Antipsychotic Drugs on Metabolic Syndrome Disturbances in First-episode Psychosis and Schizophrenia Spectrum Disorders. A Double-blind Placebo-controlled Trial.
This study has finished and is no longer accepting participants.
In PamplonaSchizophreniaMedication studyAges 18–65
- Countries
- Spain
- Sponsor
- Manuel Jesús Cuesta Zurita
CompletedNCT02627716
Official study titleEffectiveness of a Joint Crisis Plan (SOS Plan) in Preventing Relapses in Patients Diagnosed With Schizophrenia and Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including BrestSchizophreniaInterventional studyAges 18–65
- Countries
- France
- Sponsor
- University Hospital, Lille
CompletedNCT05784948
Official study titleEfficacy of Virtual Reality Mindfulness in Patients With Psychosis
This study has finished and is no longer accepting participants.
In JeonjuSchizophreniaInterventional studyAges 15–59
- Countries
- South Korea
- Sponsor
- Chonbuk National University Hospital
CompletedNCT04779177
Official study titleAn Open-label Multiple Oral Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lumateperone in Patients, Ages 13 to 17 Years, Diagnosed With Schizophrenia or Schizoaffective Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including HollywoodSchizophreniaMedication studyAges 13–17
- Countries
- United States
- Sponsor
- Intra-Cellular Therapies, Inc.
TerminatedNCT00581243
Official study titleAn Ascending Multiple-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of SLV-313 Sustained-Release (SR) Tablets Administered Orally to Subjects With Schizophrenia and Schizoaffective Disorder
This study ended early.
Location not clearly listedSchizophreniaMedication studyAges 18–50
- Countries
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
WithdrawnACTRN12614000121662
Official study titleA trial of targeted repetitive Transcranial Magnetic Stimulation (rTMS) in the treatment of auditory hallucinations in schizophrenia
This study was withdrawn before enrollment.
In AustraliaSchizophreniaInterventional studyAges 18–75
- Countries
- Australia
- Sponsor
- Professor Paul Fitzgerald
CompletedACTRN12612000217808
Official study titleNon-invasive brain stimulation and working memory enhancement in schizophrenia and healthy controls: investigating transcranial Direct Current Stimulation (tDCS) and transcranial Alternating Current Stimulation (tACS).
This study has finished and is no longer accepting participants.
In AustraliaSchizophreniaInterventional studyAges 18–65
- Countries
- Australia
- Sponsor
- Dr. Kate Hoy
CompletedACTRN12615000635561
Official study titleThe effect of canakinumab adjunctive treatment on symptoms and cognition in people with schizophrenia displaying elevated peripheral inflammatory markers
This study has finished and is no longer accepting participants.
In Elizabeth ValeSchizophreniaInterventional studyAges 18–55
- Countries
- Australia
- Sponsor
- Neuroscience Research Australia
TerminatedACTRN12622001112752
Official study titleA Multi-Centre Randomised Placebo Controlled Pilot Study of Cannabidiol for Clozapine Refractory Schizophrenia
This study ended early.
Multiple locations, including WoolloongabbaSchizophreniaInterventional studyAges 18–64
- Countries
- Australia
- Sponsor
- The University of Queensland
TerminatedACTRN12621001539820
Official study titleClozapine Obesity and Semaglutide Treatment (COaST). A randomised controlled multi-centre trial of semaglutide versus placebo for people with schizophrenia on clozapine with obesity
This study ended early.
Multiple locations, including WoolloongabbaSchizophreniaInterventional studyAges 18–64
- Countries
- Australia
- Sponsor
- The University of Queensland
CompletedNCT07043803
Official study titleReduction of Anticholinergic Medications Project (RAMP) Among Persons With Schizophrenia or Other Psychiatric Disorders Across UPMC Behavioral Healthcare Partner Organizations Using a Stepped-wedge, Randomized Trial Study Design.
This study has finished and is no longer accepting participants.
Multiple locations, including AltoonaSchizophrenia, BipolarityInterventional studyAges 18+
- Countries
- United States
- Sponsor
- University of Pittsburgh
CompletedACTRN12623001024639
Official study titleA mixed-methods randomised, 12-week cross-over randomised controlled trial to establish the feasibility, acceptability, and preliminary effectiveness of two dietary interventions (prepared meals and meal kits) vs a control condition (Coles/Myer vouchers) in community-based people living with schizophrenia who are overweight or obese.
This study has finished and is no longer accepting participants.
Multiple locations, including WoolloongabbaSchizophreniaInterventional studyAges 18–64
- Countries
- Australia
- Sponsor
- Metro South Hospital and Health Service
